TransMedics Group, Inc.
In the published model solve dated 2026-Q2, anchored at $93.35, TransMedics Group, Inc. (TMDX) is priced for today's economics sustained for ~10.0 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed July 11, 2026 from SEC EDGAR filings.
• TransMedics pairs a razor-blade device model, single-use organ-specific disposables on its OCS consoles per the FY2025 10-K, with an owned aviation and logistics network built for a market where donor organs can surface at any hospital at any time. • Profitability inverted while revenue grew: the latest quarter's revenue rose 21.2% year over year while operating margin fell from 23.2% to 7.6% across four quarters, and the 10-K now lists Terumo-backed OrganOx, XVIVO, and Paragonix as rivals in
Is TMDX overvalued? See what's priced in →
404 institutional managers reported holding TMDX in 13F filings for the quarter ended 2026-03-31. 58 opened new positions that quarter. Held by BlackRock, FMR (Fidelity), Vanguard Group, among others. On the short side, 7.7M shares were sold short as of the 2026-06-15 count, about 21% of shares outstanding (7.2 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
TMDX's share count grew 24.5% over the past five years. It pays no dividend.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at TMDX over the trailing three years: 2023: 1 buy totaling $155k; 2025: 4 buys totaling $2.98M. 13 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
TMDX's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-05 | -8.9% | -35.4% |
| 2023-11-09 | +42.6% | +41.7% |
| 2024-02-28 | +6.7% | +43.4% |
| 2024-05-03 | +20.9% | +19.0% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
TMDX's latest 8-K filings: 2026-08-04 (items 2.02, 9.01); 2026-05-21 (items 5.07, 9.01); 2026-05-05 (items 2.02, 9.01); 2026-02-27 (items 2.02, 9.01); 2026-02-24 (items 2.02, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: July 11, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.